Skip to main content

Nasal Polyposis clinical trials at UC Health
1 in progress, 0 open to eligible people

  • Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis

    Sorry, in progress, not accepting new patients

    The aim of this present study is to investigate the use of benralizumab as treatment for severe nasal polyposis. The effect of benralizumab on nasal polyps will be assessed over a 56 weeks of treatment period in patients with severe bilateral nasal polyposis who are still symptomatic despite standard of care therapy, i.e current use of intranasal corticosteroids (INCS) and prior surgery and/or use of systemic corticosteroids. The first 200 patients that complete the 56-week treatment will have a 6 month follow-up (FU) period without dosing.

    at UCLA

Last updated: